Document Type
Report
Publication Date
1998
Abstract
Depo-medroxy Progesterone Acetate (DMPA) is a progesterone-only injectable contraceptive that has been approved by the Government of India for provision in the commercial sector, where it is marketed under the brand name Depo-Provera. In 1996, it was available at rates between Rs. 140 to Rs. 180 per injection. At this price it is often beyond the reach of many women wanting a safe and effective contraceptive. In January 1996, DMPA was provided to women in three cities of Uttar Pradesh through Parivar Seva Sanstha’s (PSS) clinics at Rs. 150. In July 1996, as part of operations research (OR), the price was reduced in Agra to Rs. 50, in Varanasi to Rs. 0, and Lucknow to Rs. 100. Information was collected for 18 months to understand how price influenced demand, perceptions, and use of DMPA among urban women in Uttar Pradesh. This report states that DMPA appears to be an acceptable, safe method of contraception when offered with good client counseling and follow-up. More effective availability of the product at an affordable wholesale price in India would meet the needs of potential clients and facilitate the financial sustainability of the service by PSS.
Recommended Citation
Caleb-Varkey, Leila, John Townsend, Sneh Vishwanath, and Sudha Tiwari. 1998. "Analysis of price change on the perceptions and use of DMPA among clients using reproductive health services in Uttar Pradesh, India," Asia and Near East OR/TA Project Final Report. Dhaka: Population Council.
DOI
10.31899/rh1998.1012
Language
English
Project
Asia & Near East Operations Research and Technical Assistance Project
Included in
Demography, Population, and Ecology Commons, Health Services Research Commons, International Public Health Commons